Table 3 Changes in parameters related to IDH
NV group | PS/PES group | P | |
|---|---|---|---|
Pre-dialysis body weight (kg) | |||
Pre-observation period (zero month) | 66.7 ± 17.5 | 67.7 ± 12.4 | 0.84 |
First month | 66.7 ± 17.4 | 67.9 ± 12.4 | 0.81 |
Second month | 66.7 ± 17.5 | 67.8 ± 12.4 | 0.83 |
Third month | 66.9 ± 17.6 | 68.1 ± 12.6 | 0.80 |
Fourth month | 66.8 ± 17.6 | 68.0 ± 12.5 | 0.81 |
Fifth month | 66.6 ± 17.6 | 67.8 ± 12.7 | 0.81 |
Sixth month | 66.6 ± 17.5 | 68.1 ± 13.1 | 0.76 |
Ultrafiltration volume (ml/session) | |||
Pre-observation period (zero month) | 3071 ± 1134 | 3163 ± 996 | 0.79 |
First month | 3014 ± 1173 | 3066 ± 985 | 0.88 |
Second month | 2939 ± 1168 | 2988 ± 964 | 0.89 |
Third month | 2949 ± 1201 | 3129 ± 1015 | 0.61 |
Fourth month | 2995 ± 1171 | 3015 ± 1005 | 0.95 |
Fifth month | 3023 ± 1305 | 2956 ± 1020 | 0.86 |
Sixth month | 3028 ± 1202 | 3134 ± 1018 | 0.77 |
Cardiothoracic ratio (%) | |||
Pre-observation period (zero month) | 50.1 ± 4.9 | 50.7 ± 5.3 | 0.72 |
Sixth month | 51.4 ± 4.5 | 52.1 ± 5.6 | 0.69 |
Antihypertensive drug users (%) | |||
Pre-observation period (zero month) | 16 (80%) | 9 (45%) | 0.02 |
ARB (8) | ARB (5) | ||
Ca antag. (13) | Ca antag. (4) | ||
β blocker (3) | β blocker (3) | ||
α blocker (1) | α blocker (1) | ||
αβ blocker (1) | αβ blocker (2) | ||
Sixth month | 17 (85%) | 10 (50%) | 0.02 |
ARB (7) | ARB (6) | ||
Ca antag. (13) | Ca antag. (5) | ||
β blocker (1) | β blocker (4) | ||
α blocker (3) | α blocker (1) | ||
αβ blocker (1) | αβ blocker (2) | ||
Antiplatelet/anticoagulant users (%)a | |||
Pre-observation period (zero month) | 14 (82%) | 17 (100%) | 0.23 |
Aspirin (12) | Aspirin (15) | ||
Clopidogrel (1) | Clopidogrel (2) | ||
Warfarin (0) | Warfarin (3) | ||
EPA (0) | EPA(0) | ||
O3FAE (0) | O3FAE (0) | ||
Other (3) | Other (6) | ||
Statin (1) | Statin (3) | ||
Sixth month | 14 (82%) | 17 (100%) | 0.23 |
Aspirin (12) | Aspirin (15) | ||
Clopidogrel (3) | Clopidogrel (3) | ||
Warfarin (1) | Warfarin (2) | ||
EPA (0) | EPA (0) | ||
O3FAE (0) | O3FAE (0) | ||
Other (3) | Other (7) | ||
Statin (1) | Statin (3) | ||